MX2015003108A - Metodos de administracion de rifaximina sin producir resistencia a los antibioticos. - Google Patents

Metodos de administracion de rifaximina sin producir resistencia a los antibioticos.

Info

Publication number
MX2015003108A
MX2015003108A MX2015003108A MX2015003108A MX2015003108A MX 2015003108 A MX2015003108 A MX 2015003108A MX 2015003108 A MX2015003108 A MX 2015003108A MX 2015003108 A MX2015003108 A MX 2015003108A MX 2015003108 A MX2015003108 A MX 2015003108A
Authority
MX
Mexico
Prior art keywords
methods
antibiotic resistance
producing antibiotic
administering rifaximin
rifaximin
Prior art date
Application number
MX2015003108A
Other languages
English (en)
Inventor
Mark Pimentel
Christopher Chang
Original Assignee
Salix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Inc filed Critical Salix Pharmaceuticals Inc
Publication of MX2015003108A publication Critical patent/MX2015003108A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

Se proporcionan los métodos de administración de una composición que comprende la rifaximina a un sujeto que necesita del mismo, en donde los métodos no aumentan el desarrollo de la resistencia a rifampicina a un Staphylococcus spp. Los métodos para reducir el desarrollo de resistencia a la rifampicina a un Staphylococcus spp. también se proporcionan, que comprende administrar una composición que comprende la rifaximina a un sujeto que necesita del mismo.
MX2015003108A 2012-09-12 2013-09-12 Metodos de administracion de rifaximina sin producir resistencia a los antibioticos. MX2015003108A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261700151P 2012-09-12 2012-09-12
PCT/US2013/059415 WO2014043320A1 (en) 2012-09-12 2013-09-12 Methods of administering rifaximin without producing antibiotic resistance

Publications (1)

Publication Number Publication Date
MX2015003108A true MX2015003108A (es) 2015-09-10

Family

ID=50278666

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003108A MX2015003108A (es) 2012-09-12 2013-09-12 Metodos de administracion de rifaximina sin producir resistencia a los antibioticos.

Country Status (11)

Country Link
US (1) US20150164868A1 (es)
EP (1) EP2895169A4 (es)
JP (1) JP2015531347A (es)
CN (1) CN104955457A (es)
AU (1) AU2013315458A1 (es)
CA (1) CA2886264A1 (es)
EA (1) EA201590447A1 (es)
HK (1) HK1212633A1 (es)
MX (1) MX2015003108A (es)
TN (1) TN2015000049A1 (es)
WO (1) WO2014043320A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE890893A (fr) * 1980-11-28 1982-02-15 Erba Farmitalia Derives de rifamycine
DK0700399T3 (da) * 1993-05-24 2001-11-26 Lepetit Spa Derivater i 36-stilling af rifamyciner og anvendelse af sådanne som antimikrobemidler
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
DE69816304D1 (de) * 1997-07-29 2003-08-14 Kaneka Corp Verwendung eines rifamycinderivates zur behandlung von mastitis bei tieren
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
WO2006012470A1 (en) * 2004-07-22 2006-02-02 Cumbre Pharmaceuticals Inc. Rifamycin derivatives for treating microbial infections
MX2010009197A (es) * 2008-02-26 2010-11-22 Salix Pharmaceuticals Ltd Metodos para tratar padecimientos del intestino.
EP2278989B1 (en) * 2008-04-08 2021-05-26 Melinta Therapeutics, Inc. Oritavancin for inhibiting and treating biofilms
WO2009137672A1 (en) * 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina

Also Published As

Publication number Publication date
HK1212633A1 (zh) 2016-06-17
TN2015000049A1 (en) 2016-06-29
AU2013315458A1 (en) 2015-03-05
CA2886264A1 (en) 2014-03-20
JP2015531347A (ja) 2015-11-02
EA201590447A1 (ru) 2015-06-30
EP2895169A1 (en) 2015-07-22
EP2895169A4 (en) 2016-02-24
US20150164868A1 (en) 2015-06-18
CN104955457A (zh) 2015-09-30
WO2014043320A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
HK1210167A1 (en) Macrocycle picolinamides as fungicides -2-
HK1208463A1 (en) Macrocyclic picolinamides as fungicides -2-
HK1208034A1 (en) Macrocyclic picolinamides as fungicides -2-
EP3086640A4 (en) Macrocyclic picolinamides as fungicides
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
ZA201601726B (en) New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
MY191628A (en) Novel triazolo[4,5-d]pyrimidine derivatives
IL232463A0 (en) Antibiotic history of 2-oxo-oxazolidine-3,5-diyl
MX2015007645A (es) Cyanobacterium sp. para produccion de compuestos.
SG11201405628YA (en) Conformationally constrained, fully synthetic macrocyclic compounds
HK1199243A1 (zh) 抗菌的環戊二烯並 吡咯取代的 -二氫- 萘啶酮
HK1198550A1 (en) Polyurethane yarn, as well as fabric and swimwear using same
MX2013013463A (es) Nuevo procedimiento para la síntesis de rifaximina y una nueva forma pseudocristalina de rifaximina obtenida con el mismo.
HK1201150A1 (en) Scheme for administering n-hydroxy-4-2-[3-(n,n- dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxybenzamide n--4-2-[3-(n,n-)-2-]
GB2502390B (en) Novel Ni complex and its derivatives, producing method, and the use thereof as antioxidant
MX2016002217A (es) Compuestos con actividad pesticida.
IN2014DN10669A (es)
EP2847164A4 (en) COMPOUNDS HAVING TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS OF THESE COMPOUNDS
ZA201304074B (en) Pyrazino[2,3-d]isoxazole derivative
PL2814825T3 (pl) Dihydrofuranowe pochodne azetydyny jako środki przeciwpasożytnicze
TN2015000049A1 (en) Methods of administering rifaximin without producing antibiotic resistance
PH12015500262A1 (en) Novel pyridine derivatives
MX351093B (es) Nuevos derivados de azetidina.
UA80812U (en) ETHYL 6-THIOXO-3-(2-FURYLMETHYL)-7-CYANO-1,3,4,6-2H-PYRIDO[1,2-a][1,3,5]TRIAZINE -9-CARBOXYLATE
UA80819U (en) 2,4-DIAMINO-5-IMINO-10-(4-METHOXYPHENYL)-8-OXO-3-CYANO-7,8,9,10-TETRAHYDRO-5H-PYRIDO[2',3':2,3]THIOPYRANO[4,5-b]PYRIDINE